Disease · MONDO_0006639

adrenal cortex carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. adrenal cortex carcinoma. Diseases, record MONDO_0006639. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006639

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: adrenal cortex carcinoma; Open Targets
Open Targets ID: MONDO_0006639; Open Targets
Other names: ACC, adenocarcinoma, adrenocortical, malignant, adrenal cortex adenocarcinoma, adrenal cortex cancer, adrenal cortical adenocarcinoma, adrenal cortical carcinoma, adrenal cortical carcinoma (morphologic abnormality), adrenal cortical tumors, adrenocortical cancer, adrenocortical carcinoma, adrenocortical carcinoma (disease), cancer of the adrenal cortex, carcinoma of adrenal cortex, carcinoma of the adrenal cortex, carcinoma, adrenocortical, malignant, cortical cell carcinoma, malignant adrenocortical tumor, malignant neoplasm of adrenal cortex, malignant tumour of adrenal cortex; Open Targets
Disease Ontology: DOID:3948; Disease Ontology
Disease Ontology: DOID:3959; Disease Ontology
Disease Ontology: DOID:660; Disease Ontology
NCI Thesaurus: C9325; NCI Thesaurus
Orphanet: ORPHA:1501; Orphanet
Highest stage of its drugs: Approval, for 1 of its 46 drugs, from TTD; Open Targets

Drugs46

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MITOTANE	CHEMBL1670	Small molecule	Approval	TTD	13	12	12	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LINSITINIB	CHEMBL1091644	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
STREPTOZOCIN	CHEMBL1977579	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	9	9	9	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 46

See all 46 drugs

Targets62

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 62

See all 62 targets

Trials53

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01772004	Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)	Phase 1	1,756	2021-12-20	Solid Tumors	AVELUMAB	Its record names the disease	ClinicalTrials.gov
NCT00094497	Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)	Phase 3	304	2016-09-21	Carcinoma, Adrenal Cortical	CISPLATIN, DOXORUBICIN, ETOPOSIDE, MITOTANE, STREPTOZOCIN	Its record names the disease	ClinicalTrials.gov
NCT04400474	Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2	93	2025-06-19	Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma	ATEZOLIZUMAB, CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT00304070	Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor	Phase 3	78	2017-06-12	Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7	CISPLATIN, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, MITOTANE	Its record names the disease	ClinicalTrials.gov
NCT04187404	A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma	Phase 1/2	70	2026-01-30	Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma	NIVOLUMAB, TIGOZERTINIB	Its record names the disease	ClinicalTrials.gov
NCT00071058	Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer	Phase 2	50	2012-09-12	Adrenal Cortex Neoplasms	DOXORUBICIN, ETOPOSIDE, MITOTANE, TARIQUIDAR, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00453895	Sunitinib in Refractory Adrenocortical Carcinoma	Phase 2	39	2019-01-31	Adrenocortical Carcinoma	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT02673333	Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma	Phase 2	39	2020-01-06	Adrenocortical Carcinoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03034200	Phase 2 Study of ONC201 in Neuroendocrine Tumors	Phase 2	30	2024-11-26	Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor	DORDAVIPRONE	Its record names the disease	ClinicalTrials.gov
NCT00848016	Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery	Phase 2	29	2014-02-21	Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma	GOSSYPOL ACETIC ACID	Its record names the disease	ClinicalTrials.gov

1 to 10 of 53

See all 53 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
EDP-M vs Sz-M: Number of Disease-free Patients	6 of 151	3 of 153	304	NCT00094497	Trial comparisons
EDP-M vs Sz-M: Overall Survival	108 of 151	124 of 153	304	NCT00094497	Trial comparisons
EDP-M vs Sz-M: serious adverse events	86 of 148	62 of 149	297	NCT00094497	Trial comparisons

Papers from its trials104

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35022321	RESULT	1	PubMed
33981288	RESULT	1	PubMed
32861807	RESULT	1	PubMed
30463745	RESULT	1	PubMed
30367443	RESULT	1	PubMed
30299884	RESULT	1	PubMed
27626976	RESULT	1	PubMed
26353009	RESULT	1	PubMed
25559399	RESULT	1	PubMed
24268504	RESULT	1	PubMed

1 to 10 of 104

See all 104 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006639

GET https://conductscience.org/api/diseases/v1/MONDO_0006639/drugs?page=2

API reference For AI assistants